Kaken Pharmaceutical Co (4521) AI Stock Analysis

• Market Cap: ¥151.64B
• Dividend Yield: 4.16%
• Average Volume (3M): 164.95K
• Price to Earnings (P/E): 93.6
• Beta (1Y): 0.32
• Revenue Growth: -5.99%
• EPS Growth: -96.04%
• Country: JP
• Employees: 1,135
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 10.71
• Shares Outstanding: 44,139,730
• 10 Day Avg. Volume: 176,660
• 30 Day Avg. Volume: 164,953
• PEG Ratio: 0.17
• Price to Book (P/B): 1.12
• Price to Sales (P/S): 1.82
• P/FCF Ratio: 6.67
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 83.37
• Revenue Forecast (FY): ¥78.10B

• Rating: 80 Outperform
• Price Target: ¥4,842.00 ▲(30.44% Upside)
• Action: Reiterated Date: 09/17/25
• Date: Action: Reiterated 09/17/25

Kaken Pharmaceutical Co's strong financial performance and attractive valuation are the most significant factors contributing to its overall score. The company's stable technical indicators further support a positive outlook. However, historical volatility in revenue and cash flow suggests a need for cautious future planning.

Positive Factors

Low leverage and strong equity base

Kaken's minimal leverage and an 80% equity ratio provide durable financial flexibility to fund R&D, capex, and working capital without refinancing pressure. This low financial risk profile supports long-term stability, cushioning the business versus reimbursement shocks and enabling strategic investments.

Robust cash generation and improving FCF

Operating cash flow at over twice net income and a marked rise in free cash flow indicate strong cash conversion. Over a multi-month horizon this underpins self-funding for clinical programs, manufacturing scale or dividends, reducing reliance on external financing and enhancing resilience.

High margins and specialty dermatology focus

Elevated gross and operating margins reflect pricing power and manufacturing efficiency in branded specialty drugs. Combined with focused dermatology expertise, these structural strengths support sustainable profitability, higher cash returns per sale, and barriers to generic competition in core markets.

Negative Factors

Recent revenue decline and volatility

A nearly 19% reported revenue decline and documented historical volatility reduce predictability of cashflows and complicate multi‑period planning. Over 2–6 months this heightens execution risk for commercial and R&D investments and increases sensitivity to any further market or reimbursement shifts.

Sharp EPS contraction indicates earnings instability

An EPS decline exceeding 100% signals significant earnings swings that may stem from sales, margin pressures, or one-off items. Persistent EPS volatility undermines predictable free cash available for reinvestment or shareholder returns and raises uncertainty around financial planning and capital allocation.

Concentration and regulatory pricing risk (Japan NHI exposure)

Heavy reliance on domestic branded sales tied to Japan's NHI creates structural exposure to periodic price revisions. These regulatory-driven adjustments can materially compress unit prices and revenue, making long-term revenue visibility and margin protection dependent on policy cycles and successful product mix management.

Kaken Pharmaceutical Co Business Overview & Revenue Model

Company Description

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Kaken Pharmaceutical makes money primarily by selling prescription pharmaceuticals, with revenue recognized from product shipments to wholesalers, distributors, and/or medical institutions (depending on channel structure). Its core revenue stream is domestic Japan sales of branded drugs, where pricing and reimbursement are materially influenced by Japan’s National Health Insurance (NHI) drug pricing system; periodic NHI price revisions are therefore a key factor affecting realized unit prices and revenue. In addition to direct product sales, the company earns income from out-licensing and partnering arrangements: it can receive upfront payments, milestone payments tied to development/regulatory achievements, and ongoing royalties based on partner sales when it licenses product rights by territory or indication. Where it in-licenses products, Kaken may pay royalties or supply/technology fees, which affects profitability but not necessarily top-line revenue. The company may also generate revenue from contract manufacturing/supply arrangements (e.g., supplying active ingredients or finished products to partners) and from overseas sales routed through local partners/distributors; however, if specific magnitudes by segment are not publicly available in the provided context, they are null.

Kaken Pharmaceutical Co Financial Statement Overview

Summary

Kaken Pharmaceutical Co exhibits strong financial performance with robust profitability, solid revenue growth, and a stable balance sheet with low leverage. The company demonstrates efficient cash management, though historical volatility in revenue and cash flow suggests a need for cautious future planning.

Income Statement

Kaken Pharmaceutical Co has demonstrated strong revenue growth, with a significant increase from the previous year, and robust profitability metrics. The Gross Profit Margin and Net Profit Margin improved significantly, standing at 61.96% and 14.83% respectively in the latest year. EBIT and EBITDA margins also showed solid performances at 22.37% and 23.42%. However, the revenue growth has been somewhat volatile in the past, indicating potential market fluctuations.

Balance Sheet

The company maintains a very healthy balance sheet with a low Debt-to-Equity Ratio of 0.025, which indicates low leverage and financial stability. Return on Equity is strong at 9.14%, reflecting efficient use of equity. The Equity Ratio stands at a healthy 80.16%, signifying a strong equity base. These metrics indicate a stable financial position with minimal financial risk.

Cash Flow

Kaken Pharmaceutical Co has seen substantial growth in Free Cash Flow, with a remarkable increase in the latest year. The Operating Cash Flow to Net Income Ratio is strong at 2.14, indicating good cash generation relative to net income. Despite these strengths, historical fluctuations in cash flow and a dip in Free Cash Flow in 2024 suggest potential volatility in cash generation.

Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	94.65B	94.03B	72.04B	72.98B	76.03B	74.98B
Gross Profit	58.08B	58.26B	38.54B	39.56B	41.58B	40.91B
EBITDA	20.34B	22.02B	12.57B	9.40B	16.38B	20.99B
Net Income	12.46B	13.95B	8.03B	5.44B	9.55B	13.40B
Balance Sheet
Total Assets	176.34B	190.42B	171.62B	166.33B	165.18B	163.33B
Cash, Cash Equivalents and Short-Term Investments	55.40B	70.08B	65.32B	74.26B	74.62B	77.31B
Total Debt	3.85B	3.85B	3.85B	3.85B	3.85B	3.85B
Total Liabilities	28.89B	37.78B	27.87B	29.49B	26.86B	27.08B
Stockholders Equity	147.45B	152.63B	143.75B	136.26B	137.75B	136.26B
Cash Flow
Free Cash Flow	0.00	25.64B	410.00M	7.05B	10.08B	12.09B
Operating Cash Flow	0.00	29.78B	2.58B	9.25B	13.34B	14.38B
Investing Cash Flow	0.00	-19.65B	-5.85B	-2.63B	-7.89B	-1.64B
Financing Cash Flow	0.00	-5.37B	-5.66B	-6.99B	-8.13B	-8.75B

Kaken Pharmaceutical Co Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3712.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4521, the sentiment is Neutral. The current price of 3712 is below the 20-day moving average (MA) of 4284.50, below the 50-day MA of 4187.40, and below the 200-day MA of 3877.56, indicating a neutral trend. The MACD of 17.41 indicates Positive momentum. The RSI at 46.25 is Neutral, neither overbought nor oversold. The STOCH value of 21.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4521.

Kaken Pharmaceutical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4521	80 Outperform	¥151.64B	93.62	-2.58%	4.16%	-5.99%	-96.04%
4534	73 Outperform	¥119.61B	12.60	4.81%	2.34%	4.35%	48.30%
4569	69 Neutral	¥85.43B	8.41	―	3.36%	11.65%	93.46%
4553	67 Neutral	¥202.27B	5.05	12.02%	2.14%	9.32%	30.85%
4547	66 Neutral	¥183.61B	14.92	6.70%	2.48%	13.11%	41.57%
4887	59 Neutral	¥211.57B	13.89	―	2.28%	12.78%	-105.43%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%